Should You Buy This Growth Stock Following a Major Approval?
The past three years have been a southbound roller coaster for Bluebird Bio (NASDAQ: BLUE). The small-cap biotech encountered a series of headwinds, losing 90% of its value. Should investors consider purchasing shares of this beaten-down biotech stock now?